No abstract

No abstract

among survivors has been acceptable with no severe (>grade 3) side effects noted. Conclusion: We have been able to successfully deliver a total dose of up to 1800 cGy to the entire bony skeleton with our TMI technique without observing any dose-limiting toxicity among the patients. Further dose-escalation appears feasible, and treatment response is encouraging since the median time to relapse post second ASCT in this high-risk population appears to be consistent with that reported in the literature. We are now in the process of increasing the total dose to 2000 cGy/10fr/bid/5 days.

The use of consolidative RT after HDC and ASCT for relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ≥ 2 cm after ASCT, improved 2-year PFS and OS were seen. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative RT in the ASCT setting.

No abstract

No abstract

No abstract

No abstract